glp 1 and indigestion from GLP-1 Injections GLP-1 and GIP-1 receptor agonists
Description
Results Over the course of the last year in the overall- and paired populations there was an increase in BMI (median [IQR] 25.7 [22.8-30.0] to 26.7 [23.8-31.1] kg/m2, p=6.4x10-5 and 26.8 [23.4-31.7] to 27.1 [23.8-31.8] kg/m2, p=3.7x10-4, respectively) and overweight and obesity ([figure 1A][1])
Recently, SGLT2i and GLP1- RAs have emerged as potential therapeutic tools preventing the transition from acute to chronic kidney disease due to their efficacy in preserving renal function
Why This Matters This research shifts our understanding of GLP-1s from "weight loss drugs with side benefits" to targeted metabolic therapies
Menu items feature high-protein smoothies (20g+), zero grams of added sugar, and "rich" in fiber
Ever heard of the term "food baby"
